🔎 Trials Near Me

Home › Lung Cancer › NCT06716580

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

RecruitingHealthy volunteers welcome

Who can join

Ages 40 to 80 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria (Aims 1, 2, and 3)

Group 1 - Healthy Individuals (50-80 years of age):

Non-tobacco using (currently). Self-identify as East Asian (including Southeast Asian) or Latinx/Hispanic. East Asian includes those who self-identify as Chinese, Japanese, Korean, Taiwanese, or Malaysian.

Southeast Asian includes those who self-identify as Cambodian, Thai, Vietnamese, or Filipino.

Latinx/Hispanic includes those who self-identify as a person of Central or South American or Caribbean culture or origin.

Countries of origin include:

East Asian: China, Japan, Korea, Mongolia, Singapore, Taiwan.

Southeast Asian: Brunei, Cambodia, Philippines, Laos, Malaysia, Myanmar, Thailand, Timor-Leste, Vietnam.

Latinx/Hispanic: Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Spain, Suriname, Trinidad and Tobago, Uruguay, Venezuela.

Group 2 - At-Risk Individuals (40-80 years of age):

Non-tobacco using (currently).

Individuals of any race or ethnicity who meet at least one of the following criteria:

Family history of any EGFR-mutant lung cancer. Personal history of chest radiation. History of tuberculosis (TB) infection, asthma requiring daily inhaled corticosteroids, or chronic bronchitis.

Symptoms of lung cancer for the past month, including unexplained weight loss, voice hoarseness, cough or worsening cough, or dyspnea or worsening dyspnea.

Excluding individuals who concurrently present with a viral infection, runny nose, sore throat, or productive cough with green or yellow sputum.

Additional Inclusion Criteria for Groups 1 and 2:

Aims 1 and 2: Able to complete and understand the study's informed consent in their preferred language.

Aim 3: Able to complete and understand the study's informed consent and participate in a focus group in English, Mandarin, Vietnamese, or Spanish.

Exclusion Criteria (Aims 1, 2, and 3) for Groups 1 and 2:

Having had a chest CT scan in the last 12 months or having an anticipated chest CT scan during the enrollment period.

Having a current cancer or history of cancer within the last 3 years, excluding localized skin cancer, breast ductal carcinoma in situ, and localized prostate cancer.

Hemoptysis. More than 400 lifetime cigarettes (i.e., 20 packs) of smoking or tobacco use. Adults unable to provide informed consent. Individuals younger than 40 years of age. Prisoners. Pregnant women. Personal diagnosis of lung cancer or testing for clinical suspicion of lung cancer.

Not able to comply with study requirements.

About the study

This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening.

The name of the test used in this research study is:

-Circulating free DNA (cfDNA) Assay

What is being tested

Sponsor: Dana-Farber Cancer Institute · Participants: 1,000 · Started: Apr 1, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06716580

Locations in the U.S.

MassachusettsBeth Israel Deaconess Medical Center, Boston (Not yet recruiting)
Dana-Farber Cancer Institute, Boston
Massachusetts General Hospital, Boston (Not yet recruiting)
Dana-Farber Cancer Institute at Steward St. Elizabeth's, Brighton (Not yet recruiting)
Dana-Farber Cancer Instiute Merrimack Valley, Methuen (Not yet recruiting)
Dana-Farber Cancer Institute South Shore, South Weymouth (Not yet recruiting)

Conditions

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.